|
Lupus Erythematosus, Systemic
|
0.700 |
Biomarker
|
disease |
BEFREE |
IL10/TNFalpha interaction influences susceptibility to DLE and the appearance of specific autoantibodies in SLE patients, whereas high TNFalpha producer genotypes represent a significant risk factor for SLE.
|
15800006 |
2005 |
|
Lupus Erythematosus, Systemic
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
IL-10 and TNF-alpha promoter polymorphisms in susceptibility to systemic lupus erythematosus in Taiwan.
|
20576226 |
2010 |
|
Lupus Erythematosus, Systemic
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Interleukin-10 promoter polymorphisms and expression in Thai children with juvenile systemic lupus erythematosus.
|
23640982 |
2013 |
|
Lupus Erythematosus, Systemic
|
0.700 |
Biomarker
|
disease |
BEFREE |
IL-10, IL-9 and IL-15-mediated JAK/STAT signalling was shown to be involved in the pathological amplification of IFN responses observed in SLE.
|
24391825 |
2013 |
|
Lupus Erythematosus, Systemic
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
IL10 confirmed its association with SLE [rs3024505: P = 0.02, OR = 1.52 (95% CI: 1.07-2.16)].
|
25369137 |
2014 |
|
Lupus Erythematosus, Systemic
|
0.700 |
Biomarker
|
disease |
BEFREE |
IL-10 deregulation plays a role in the development of a large number of inflammatory diseases such as neuropathic pain, Parkinson's disease, Alzheimer's disease, osteoarthritis, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, type 1 diabetes, inflammatory bowel disease, and allergy.
|
28799796 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.700 |
Biomarker
|
disease |
BEFREE |
IL10 was also increased in SLE patients with CGT (-592/-1082/-819) haplotype.
|
30430731 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.700 |
Biomarker
|
disease |
BEFREE |
IL-10 production is increased in RA, SS, and SLE.
|
7980676 |
1994 |
|
Lupus Erythematosus, Systemic
|
0.700 |
Biomarker
|
disease |
BEFREE |
IL-10 overproduction in SLE suggests that this Th2-type interleukin plays a role in the production of autoantibodies through pathways involving both paracrine production by monocytes and autocrine IL-10 production by autoreactive B cells.
|
8186374 |
1994 |
|
Lupus Erythematosus, Systemic
|
0.700 |
Biomarker
|
disease |
BEFREE |
A better understanding of the role of IL-10 in B-cell responses and lupus would allow to identify the most promising therapies for individual SLE patients in the future.
|
31735515 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A decreased risk of SLE in the IL10-819C/T and IL10-592C/A polymorphisms in subgroups was also observed, but further rigorously studies are needed to confirm these results.
|
30183604 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A meta-analysis of all published results indicates a possible direct role of the IL10.G repeat number in SLE susceptibility.
|
12486603 |
2002 |
|
Lupus Erythematosus, Systemic
|
0.700 |
AlteredExpression
|
disease |
LHGDN |
A meta-analysis of all published results indicates a possible direct role of the IL10.G repeat number in SLE susceptibility.
|
12486603 |
2002 |
|
Lupus Erythematosus, Systemic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Adipose tissue-derived mesenchymal stem cells induce expansion of interleukin-10-producing regulatory B cells and ameliorate autoimmunity in a murine model of systemic lupus erythematosus.
|
25506685 |
2015 |
|
Lupus Erythematosus, Systemic
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Among identified SNPs, the rare C allele of IL10-592A-->C was significantly associated with the SDI among SLE patients in the following three alternative models: codominant (P = 0.007, odds ratio = 1.70), dominant (P = 0.02, odds ratio = 1.85) and recessive (P = 0.05, odds ratio = 2.25).
|
16287924 |
2006 |
|
Lupus Erythematosus, Systemic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Analysis of immunoglobulin-like transcripts (ILTs) in lymphocytes with sHLA-G and IL10 from SLE patients.
|
22562117 |
2013 |
|
Lupus Erythematosus, Systemic
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Anti-inflammatory cytokines included IL-4 IL-10, which were upregulated in SLE-I sera (but not SLE-A), controlling clinical phenotypes.
|
31781106 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Association of the -1082G/A polymorphism in the interleukin-10 gene with systemic lupus erythematosus: a meta-analysis.
|
23415626 |
2013 |
|
Lupus Erythematosus, Systemic
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Associations have been reported between single nucleotide polymorphisms (SNPs) of IL-10 and the Ile50Val polymorphism of the IL-4 receptor gene (IL-4R) gene and atopy and autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis.
|
15497451 |
2004 |
|
Lupus Erythematosus, Systemic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Because of its B cell-promoting effects, IL-10 may contribute to autoantibody production and tissue damage in SLE.
|
25187566 |
2014 |
|
Lupus Erythematosus, Systemic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Because the exact mechanism of IL-10 signalling in the pathogenesis of SLE is unclear, this study sought to assess the expression and signalling of interleukin-10 receptor (IL-10R) in peripheral leucocytes from patients with SLE.
|
21635228 |
2011 |
|
Lupus Erythematosus, Systemic
|
0.700 |
Biomarker
|
disease |
LHGDN |
By contrast, IL-10 enhanced ROI production and cell death in lupus PBL without affecting ROI levels and survival of control PBL.
|
12097418 |
2002 |
|
Lupus Erythematosus, Systemic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Co-expression levels of p-Elk-1 and IL-10 were elevated in SLE T, B cells and monocytes, associated with increased disease activity in SLE B cells, and were best downregulated by ERK inhibitor.
|
24130510 |
2013 |
|
Lupus Erythematosus, Systemic
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Conversely, the IL-10 CA20 allele showed a protective effect of SLE susceptibility.
|
16412052 |
2006 |
|
Lupus Erythematosus, Systemic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Cytokines levels were measured by cytometric bead array technique. cSLE patients had higher IL-6 (P<0.001) and IL-10 (P<0.001) levels than healthy controls.
|
28380214 |
2017 |